{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:23:25Z","timestamp":1787750605488,"version":"build-2784847793"},"reference-count":22,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adult acne vulgaris is a chronic inflammatory skin condition that primarily affects females. Initial management includes topical and oral medications, but important limitations include ineffectiveness, nonadherence, and adverse effects. Spironolactone has shown good results in off\u2010label acne management.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>We aim to conduct a systematic review and meta\u2010analysis exploring the safety and efficacy of oral spironolactone for females with acne.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched PubMed, Embase, and Cochrane for randomized controlled trials (RCTs) comparing oral spironolactone in women with acne to placebo. The primary endpoint was the objective assessment of acne improvement. Secondary endpoints included subjective assessment and adverse events. Statistical analysis was performed using Review Manager 5.4. Heterogeneity was assessed with <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> statistics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 563 patients from 5 RCTs, of which 251 (42.9%) received spironolactone. Objective assessment of acne improvement (OR 6.59; 95% 3.50\u201312.43; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00001; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%) was sixfold higher in the spironolactone group compared with placebo. Subjective assessment showed no difference between the two groups (OR 5.22; 95% 0.62\u201344.24; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.13; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200985%). Menstrual irregularities (OR 1.09; 95% 0.37\u20133.25; <jats:italic>p<\/jats:italic>\u2009=\u20090.88; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200933%) and breast enlargement (OR 1.37; 95% 0.79\u20132.38; <jats:italic>p<\/jats:italic>\u2009=\u20090.26; <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090%) were nonsignificant in patients taking spironolactone. Trial sequential analysis (TSA) confirmed that the required sample size was reached, favoring spironolactone over placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our study suggests that oral spironolactone improves acne in female patients compared to placebo without increasing risks; thus, it should be elevated from \u201coff\u2010label\u201d use to an officially recommended standard of care.<\/jats:p><\/jats:sec><jats:sec><jats:title><jats:styled-content style=\"fixed-case\">PROSPERO<\/jats:styled-content> Registration<\/jats:title><jats:p>CRD42024626984.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.70411","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T10:24:35Z","timestamp":1755512675000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and Safety of Oral Spironolactone for Women With Acne Vulgaris: A Systematic Review and Meta\u2010Analysis of Randomized Placebo\u2010Controlled Trials With Trial Sequential Analysis"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7918-0107","authenticated-orcid":false,"given":"Laura","family":"Ghanem","sequence":"first","affiliation":[{"name":"Faculty of Medical Sciences Lebanese University  Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4936-7008","authenticated-orcid":false,"given":"Najwaa","family":"Kirmani","sequence":"additional","affiliation":[{"name":"Dow Medical College  Karachi Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9680-0078","authenticated-orcid":false,"given":"Nathalia","family":"De Le\u00f3n Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Universidad de los Andes  Bogot\u00e1 Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3589-4318","authenticated-orcid":false,"given":"Mar\u00eda Paula","family":"Palacios\u2010Ortiz","sequence":"additional","affiliation":[{"name":"Universidad San Francisco de Quito  Quito Ecuador"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1062-4859","authenticated-orcid":false,"given":"Juan David","family":"Rodr\u00edguez\u2010Parra","sequence":"additional","affiliation":[{"name":"Pontificia Universidad Javeriana  Bogot\u00e1 Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5871-9853","authenticated-orcid":false,"given":"Corina A.","family":"Rusu","sequence":"additional","affiliation":[{"name":"Dermatology Department University of Virginia  Charlottesville Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2023.101578"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13462"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.12.017"},{"key":"e_1_2_13_5_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cAcne Vulgaris: Management \u201d(2021) https:\/\/www.nice.org.uk\/guidance\/ng198\/chapter\/Recommendations."},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806\u20104841.20198203"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj\u20102022\u2010074349"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.15559"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102133.1984.tb04045.x"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102133.1986.tb05722.x"},{"key":"e_1_2_13_11_1","first-page":"1","article-title":"Effect of Spironolactone on Acne Vulgaris: A Double Blind Study","volume":"17","author":"Mansurul A.","year":"2000","journal-title":"Bangladesh Journal of Dermatology, Venereology and Leprology"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13518"},{"key":"e_1_2_13_14_1","unstructured":"\u201cResearch C for DE and Acne Vulgaris: Establishing Effectiveness of Drugs Intended for Treatment \u201dApril 21 2020 accessed January 1 2025 https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/acne\u2010vulgaris\u2010establishing\u2010effectiveness\u2010drugs\u2010intended\u2010treatment."},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010016\u20100245\u2010x"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0298155"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.34"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.07.1446"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.16637"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403\u2010024\u201003430\u20101"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.26002"},{"key":"e_1_2_13_23_1","unstructured":"\u201cStubborn Acne? Hormonal Therapy May Help \u201daccessed January 3 2025 https:\/\/www.aad.org\/public\/diseases\/acne\/derm\u2010treat\/hormonal\u2010therapy."}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.70411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T02:04:01Z","timestamp":1760061841000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.70411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/jocd.70411"],"URL":"https:\/\/doi.org\/10.1111\/jocd.70411","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"2025-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70411"}}